Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | EIF2AK2 | P19525 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042442 | 0.91 | HTR1A (0.42) | PTGDR2PTGS1MAP3K14MAPTKDM4E | |
| SCHEMBL2961240 | 0.88 | MAP3K14 (0.48) | PTGDR2PTGS1MAP3K14TLR8EIF2AK2 | |
| SCHEMBL2962412 | 0.85 | PTGS2 (0.46) | PTGDR2PTGS1MAP3K14TLR8EIF2AK2 | |
| SCHEMBL317795 | 0.83 | HTR2A (0.46) | PTGDR2PTGS1MAP3K14TLR8EIF2AK2 | |
| SCHEMBL2951882 | 0.82 | KIF11 (0.49) | PTGDR2PTGS1MAP3K14EIF2AK2MEN1 | |
| SCHEMBL317801 | 0.82 | PTGDR2 (0.53) | PTGDR2PTGS1KDM4EMEN1KMT2A | |
| SCHEMBL2954873 | 0.80 | TLR8 (0.44) | PTGDR2PTGS1MAP3K14TLR8EIF2AK2 | |
| SCHEMBL2962434 | 0.79 | TLR8 (0.44) | PTGDR2PTGS1MAP3K14TLR8KDM4E | |
| SCHEMBL317503 | 0.78 | KIF11 (0.46) | PTGDR2PTGS1MAP3K14EIF2AK2MEN1 | |
| SCHEMBL317189 | 0.78 | PTGDR2 (0.53) | PTGDR2PTGS1MAP3K14EIF2AK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093278-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20100210685-A1 | Novel Substituted Indoles | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | IDO1, IDO2, TPH1 | PTGDR2 429/4885PTGS1 413/4885MAP3K14 3677/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | PTGDR2 54/4885PTGS1 191/4885MAP3K14 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.